Advertisement
Advertisement
CRVS
Corvus Pharmaceuticals, Inc.
10.54
USDSponsored
+0.81
+8.32%
Nov 06, 15:59 UTC -5
Closed
After-Market
10.63
+0.10
+0.90%
Corvus Pharmaceuticals, Inc. (CRVS) Earnings
CRVS Earnings Reports
Positive Surprise Ratio
CRVS beat 22 of 43 last estimates.
51%
Next Report
Date of Next Report
Mar 10, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.22
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/+46.67%
Corvus Pharmaceuticals, Inc. earnings per share and revenue
On Nov 05, 2026, CRVS reported earnings of -0.22 USD per share (EPS) for Q3 26, missing the estimate of -0.20 USD, resulting in a -7.06% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +8.32% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.22 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were Corvus Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Corvus Pharmaceuticals, Inc. reported EPS of -$0.22, missing estimates by -7.06%, and revenue of $0.00, 0% as expectations.
How did the market react to Corvus Pharmaceuticals, Inc.'s Q3 2026 earnings?
The stock price moved up 8.32%, changed from $9.73 before the earnings release to $10.54 the day after.
When is Corvus Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Mar 10, 2027.
What are the forecasts for Corvus Pharmaceuticals, Inc.'s next earnings report?
Based on --
analysts, Corvus Pharmaceuticals, Inc. is expected to report EPS of -$0.22 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.